Neagen and Visiopharm announce new Technical Integration between image analysis and PACS to meet demands from pathologists


Hørsholm – Denmark, September 5th, 2017 - Neagen and Visiopharm today announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.

Visiopharm is a worldwide leader of Augmented Pathology™ within tissue research and diagnostics and Neagen offers a true vendor neutral enterprise imaging system based on worldwide DICOM standard.

“We are excited to see an increased demand for both workflow automation and improved interpretive accuracy from pathologists in Finland. These are the two areas where Visiopharm makes a real difference. By integrating our Augmented Pathology™ software with neaLink, customers can now integrate precision pathology into PACS-driven workflows, to achieve better data quality, turnaround times, and reduce manual labor”, says Michael Grunkin, CEO Visiopharm.

“Neagen sees digital pathology as indispensable in the modern pathology lab, and seamless integration into other existing diagnostic medical workflows is a pivotal requirement to successful deployment. neaLink VNA is a modern and scalable enterprise imaging solution for all medical disciplines. With this technical integration, our customers across the globe will be able to combine advanced image analysis to digital pathology with radiology in a seamlessly integrated digital workflow, to further enhance neaLink as a platform for integrated diagnostics”, says Lasse Jyrkinen, CEO Neagen.

The Oncotopix® solution is compatible with and validated for all major scanner formats, and has been validated and CE-marked for the three major reagent vendors. Making Oncotopix® available as a simple and seamlessly integrated plug-in to PACS and LIS systems, makes it possible to deploy and scale digital pathology in the lab, one cost-efficient and risk-free step at a time.

For further information, please contact:

Lasse Jyrkinen, CEO

Neagen Oy

Tel: +358 40 539 3163


Helle Fisker, CMO

Visiopharm A/S

Tel: +45 29178777




About Neagen

Neagen is a true pioneer in the enterprise imaging by supporting fully digital workflow for all the medical specialties. Company is dedicated to support storing and distributing all medical images, videos and reports according to the DICOM standard since 2003.

Neagen has invested a lot in developing a true vendor neutral archive approach (VNA) and are proud that when receiving incoming data, regardless of it’s format Neagen software will automatically convert this to DICOM format. This innovative feature means patient data can not only be stored for longer, it can also be viewed and/or distributed in optical condition during this period - something that most medical devices and IT systems cannot guarantee. Neagen's digital pathology solution is a continuation of our vision, thus there is no compromises on workflow efficiency or conformance with the standards.

Neagen is a privately-owned company and has its headquarter in Helsinki, Finland and R&D facility in Oulu, Finland.

About Visiopharm

Visiopharm is a vendor-neutral provider of Augmented Pathology comprising high throughput and precision pathology for digital and automated test applications. Through its many partnerships and expertise in intelligent image analysis Visiopharm solutions span across the entire digital pathology workflow modernising and improving anatomic pathology laboratory routines worldwide. In EU Visiopharm offers several IVD algorithms as an aid to the pathologists doing breast cancer diagnostics. Recently Visiopharm launched a new Viewer completely innovating smooth and seamless navigation for routine analysis.

Visiopharm’s software is featured in over 1200 scientific publications, and has over 800 licenses placed, with countless users, in more than 30 countries. Headquartered in the Medicon Valley of Denmark, with a branch office in Sweden, the Netherlands, and North America in Broomfield, Colorado.

Hørsholm, Denmark, May 3rd - Visiopharm A/S announces the first result of their multifaceted strategy to apply Deep Learning technologies to its leading image analysis solution for cancer research and diagnostics. Visiopharm considers Deep Learning an important technological breakthrough for tissue pathology that offers the potential to make a real difference in the assessment of tissue structures, which is probably one of the most complex and challenging applications of image analysis.

Real progress in this field requires a multi-disciplinary approach and therefore Visiopharm has established a broad multidisciplinary strategy to lead further development of Deep Learning in tissue pathology, within several important clinical and research applications.  To support this strategy Visiopharm has established an International Consortium for Deep Learning in Tissue Pathology. The consortium involves Academic Medical Centers, Tissue Biobanks, Engineering Universities, Biopharmaceutical companies, and other industrial partners who all share this vision.  “We are very excited about our fast progress in deep learning over the past year and Visiopharm remains committed to investing a lot more in this technology .  We are currently formalizing the consortium and we look forward to continued collaborations and sharing more details on this initiative soon” says Michael Grunkin, CEO of Visiopharm.  

Read more

OracleBio, a global leader in high precision, quantitative digital image analysis services, is pleased to announce an expansion of its software capabilities to include Visiopharm Oncotopix®. Produced by Denmark-based Visiopharm, Oncotopix® software is an advanced platform for computer assisted quantification of immunohistochemistry (IHC) and In-Situ Hybridization (ISH) staining. Oncotopix offers a portfolio of software modules designed for application within cancer diagnostics and for scientists within cancer research and drug development.

Read more

Visiopharm A/S acquires LRI Imaging AB to become a leader in Diagnostic Digital Pathology 


For Scandinavain readers, see the article from MedWatch here
For International readers, see the article from here

Hørsholm, Denmark, December 1st -  Visiopharm A/S today announces its acquisition of LRI Imaging AB. With more than 10 years of experience in the field, many successful installations in routine diagnostic pathology labs, LRI Imaging AB is the leading diagnostic digital pathology provider in Sweden. Today, Visiopharm A/S has implemented diagnostic digital pathology at a national scale in Denmark, as well as several other systems in Europe.

With a staff of almost 50 digital pathology experts, Visiopharm A/S and LRI Imaging AB are jointly becoming a highly specialized European leader in Diagnostic Digital Pathology solutions.

“We are now seeing diagnostic digital pathology take off; and not just in Scandinavia, but in large parts of Europe. An important experience from the last 10 years is that going digital is a major undertaking for the pathology lab. We are excited about this merger, which allow us to offer our joint experience and expertise in helping diagnostic pathology labs going digital - one cost-efficient and risk-free step at a time. Our joint expertise gives us a depth of practical expertise in all critical aspects of digital pathology, allowing us to become a true partner in helping pathology labs both implement and take full advantage of this type of technology”, says Michael Grunkin CEO of Visiopharm

Rickard Lindelöf, CEO of LRI Imaging / Visiopharm AB, adds: “For almost a decade we have provided diagnostic digital pathology solutions to Swedish pathology labs. We have done that by integrating best-of-breed solution components.  The technology developed by Visiopharm allow us to finally realize the full potential of diagnostic digital pathology: Integrating image analysis in LIS-driven workflows, which is giving pathologists access to validated technology that will improve both data quality and productivity while reducing costs and turnaround times”.

“We have been running several large clinical studies using this technology, of which some have already been published. That has allowed us to see firsthand to what extent image analysis, if used in the right way, can give significant improvements in diagnostic data quality. We believe this will have a great impact on patient safety. And we are excited to see such technology integrated in an open end-to-end digital pathology solution. We are convinced that digital pathology will lead to improvements in the patient care and help us cope with the growing case load and complexity all diagnostic labs are experiencing. This will benefit both patients individually and society in general”, says Johan Hartman, Associate Professor at Karolinska University Hospital.

Read more